{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:29:16Z","timestamp":1789399756557,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jocn.2025.111602","type":"journal-article","created":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T00:40:38Z","timestamp":1756773638000},"page":"111602","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Stereotactic radiosurgery for brain metastases from extra-renal clear cell carcinoma: A series of four patients and review of the literature"],"prefix":"10.1016","volume":"141","author":[{"given":"Paul M.","family":"Harary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke S.","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahed H.","family":"Kattaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred C.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deya","family":"Abu-Reesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara C.","family":"Emrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Tayag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Ustrzynski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erqi L.","family":"Pollom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie Hayden","family":"Gephart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","article-title":"Differences in tumor type in low-stage versus high-stage ovarian carcinomas","volume":"29","author":"K\u00f6bel","year":"2010","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.jocn.2025.111602_b0010","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3802\/jgo.2013.24.4.342","article-title":"Trends in incidence and survival outcome of epithelial ovarian cancer: 30-year national population-based registry in Taiwan","volume":"24","author":"Chiang","year":"2013","journal-title":"J Gynecol Oncol"},{"issue":"Supp 3","key":"10.1016\/j.jocn.2025.111602_b0015","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary","volume":"24","author":"Okamoto","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jocn.2025.111602_b0020","doi-asserted-by":"crossref","unstructured":"Kim SI, Lim MC, Lim J, et al. Incidence of epithelial ovarian cancer according to histologic subtypes in Korea, 1999 to 2012. J Gynecol Oncol 2016;27(1).","DOI":"10.3802\/jgo.2016.27.e5"},{"issue":"6","key":"10.1016\/j.jocn.2025.111602_b0025","doi-asserted-by":"crossref","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int J Gynecol Cancer"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0030","first-page":"6","article-title":"Clear cell adenocarcinoma of the lung and its driver mutation","volume":"1","author":"Stopsack","year":"2013","journal-title":"Cancer Treatm Commun"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0035","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.prp.2017.02.013","article-title":"Clear cell colorectal carcinoma: time to clarify diagnosis","volume":"213","author":"Remo","year":"2017","journal-title":"Pathol Res Pract"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/COC.0000000000000641","article-title":"Genomic and molecular abnormalities in gynecologic clear cell carcinoma","volume":"43","author":"Marks","year":"2020","journal-title":"Am J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0045","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.ygyno.2008.02.006","article-title":"Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? a study of 1411 clear cell ovarian cancers","volume":"109","author":"Chan","year":"2008","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.jocn.2025.111602_b0050","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0055","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1006\/gyno.1996.0065","article-title":"Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease","volume":"60","author":"Goff","year":"1996","journal-title":"Gynecol Oncol"},{"issue":"24","key":"10.1016\/j.jocn.2025.111602_b0060","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1200\/JCO.2016.66.9010","article-title":"Randomized phase III trial of irinotecan plus cisplatin compared with paclitaxel plus carboplatin as first-line chemotherapy for ovarian clear cell carcinoma: JGOG3017\/GCIG trial","volume":"34","author":"Sugiyama","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0065","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"17_suppl","key":"10.1016\/j.jocn.2025.111602_b0070","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA5500","article-title":"Final results of BrUOG 354: a randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas","volume":"42","author":"Dizon","year":"2024","journal-title":"JCO"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0075","doi-asserted-by":"crossref","DOI":"10.3171\/2023.5.FOCUS23115","article-title":"Surgical management of brain metastasis from ovarian cancer: a systematic review and case series","volume":"55","author":"Costello","year":"2023","journal-title":"Neurosurg Focus"},{"issue":"6","key":"10.1016\/j.jocn.2025.111602_b0080","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/j.jocn.2004.08.021","article-title":"Multiple cerebral and leptomeningeal metastases from ovarian carcinoma: unusual early presentation","volume":"12","author":"al Barbarawi","year":"2005","journal-title":"J Clin Neurosci"},{"issue":"8","key":"10.1016\/j.jocn.2025.111602_b0085","doi-asserted-by":"crossref","first-page":"E228","DOI":"10.1002\/dc.25145","article-title":"Cerebrospinal fluid-dissemination of a ovarian clear cell carcinoma: a leptomeningial carcinomatosis with diagnostic challenges","volume":"51","author":"Koyuncuer","year":"2023","journal-title":"Diagn Cytopathol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0090","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000014020","article-title":"Brain metastasis from ovarian clear cell carcinoma: a case report","volume":"98","author":"Liu","year":"2019","journal-title":"Medicine"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0095","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/neup.12172","article-title":"Metastatic ovarian carcinoma to the brain: an approach to identification and classification for neuropathologists","volume":"35","author":"Nafisi","year":"2015","journal-title":"Neuropathology"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0100","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/PGP.0000000000000550","article-title":"Cerebellar metastasis from ovarian carcinoma harboring PIK3CA-activating Mutation: a \u201cclear\u201d explanation for unexpected \u201cvertigo.","volume":"39","author":"Piermattei","year":"2020","journal-title":"Int J Gynecol Pathol"},{"issue":"7","key":"10.1016\/j.jocn.2025.111602_b0105","first-page":"1243","article-title":"A case of brain metastasis from advanced ovarian clear-cell carcinoma during maintenance chemotherapy with irinotecan+ cisplatin","volume":"35","author":"Takami","year":"2008","journal-title":"Gan to Kagaku ryoho Cancer & Chemotherapy"},{"key":"10.1016\/j.jocn.2025.111602_b0110","article-title":"Case report of two long term ovarian cancer survivors with brain metastases following multimodal treatment including chemotherapy, radiotherapy and maintenance olaparib: an institutional case series and literature review","volume":"54","author":"Tsuchino","year":"2024","journal-title":"Gynecol Oncol Rep"},{"key":"10.1016\/j.jocn.2025.111602_b0115","article-title":"Late recurrence of clear-cell adenocarcinoma of the cervix: case report","author":"Burks","year":"1990","journal-title":"Obstet Gynecol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0120","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/j.ejrex.2009.06.005","article-title":"Intraventricular metastasis from a clear cell carcinoma of uterine cervix","volume":"72","author":"Ulu","year":"2009","journal-title":"Europ J Radiol Extra"},{"issue":"9","key":"10.1016\/j.jocn.2025.111602_b0125","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1002\/cncr.23868","article-title":"Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery","volume":"113","author":"Monaco","year":"2008","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jocn.2025.111602_b0130","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.3171\/2021.12.JNS212239","article-title":"Gamma Knife radiosurgery for metastatic brain tumors from ovarian cancer: histopathological analysis of survival and local control. a Japanese multi-institutional cooperative and retrospective cohort study","volume":"137","author":"Matsunaga","year":"2022","journal-title":"J Neurosurg"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0135","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.3892\/ol.2017.5621","article-title":"Stereotactic radiosurgery for brain metastasis from gynecological malignancies","volume":"13","author":"Kasper","year":"2017","journal-title":"Oncol Lett"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0140","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1006\/gyno.1997.4642","article-title":"Successful treatment of brain metastases from ovarian cancer using gamma-knife radiosurgery","volume":"65","author":"Kawana","year":"1997","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.jocn.2025.111602_b0145","doi-asserted-by":"crossref","first-page":"4010","DOI":"10.3390\/cancers3044010","article-title":"Role of radiation therapy in the management of renal cell cancer","volume":"3","author":"Blanco","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.jocn.2025.111602_b0150","doi-asserted-by":"crossref","unstructured":"Kim YH, Kim JW, Chung HT, Paek SH, Kim DG, Jung HW. Brain metastasis from renal cell carcinoma. In: Current and Future Management of Brain Metastasis. Vol 25. Karger Publishers; 2012:163-175.","DOI":"10.1159\/000331190"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0155","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s11060-015-1871-5","article-title":"Control of brain metastases from radioresistant tumors treated by stereotactic radiosurgery","volume":"124","author":"Yaeh","year":"2015","journal-title":"J Neurooncol"},{"issue":"Supplement","key":"10.1016\/j.jocn.2025.111602_b0160","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3171\/JNS\/2008\/109\/12\/S19","article-title":"Gamma Knife surgery in the management of radioresistant brain metastases in high-risk patients with melanoma, renal cell carcinoma, and sarcoma","volume":"109","author":"Powell","year":"2008","journal-title":"J Neurosurg"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0165","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606","volume":"34","author":"Kr\u00e4mer","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0170","doi-asserted-by":"crossref","first-page":"71","DOI":"10.6004\/jnccn.2022.0001","article-title":"Kidney cancer, version 3.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Motzer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"627","key":"10.1016\/j.jocn.2025.111602_b0175","first-page":"10","article-title":"Radiobiology for the radiologist","volume":"66","author":"Hall","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0180","article-title":"Radiobiology of radiosurgery for the central nervous system","volume":"2013","author":"Santacroce","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jocn.2025.111602_b0185","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2016.03.081","article-title":"RECIST 1.1\u2014Update and clarification: from the RECIST committee","volume":"62","author":"Schwartz","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7172","key":"10.1016\/j.jocn.2025.111602_b0190","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1136\/bmj.317.7172.1572","article-title":"Survival probabilities (the Kaplan-Meier method)","volume":"317","author":"Bland","year":"1998","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0195","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1109\/TR.1986.4335330","article-title":"The statistical analysis of failure data","volume":"35","author":"Kalbfleisch","year":"1986","journal-title":"IEEE Trans Reliab"},{"key":"10.1016\/j.jocn.2025.111602_b0200","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.jocn.2025.111602_b0205","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"issue":"4","key":"10.1016\/j.jocn.2025.111602_b0210","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/GIM.0b013e31816b5cae","article-title":"ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007","volume":"10","author":"Richards","year":"2008","journal-title":"Genet Med"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0215","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/cge.12257","article-title":"A systematic approach to assessing the clinical significance of genetic variants","volume":"84","author":"Duzkale","year":"2013","journal-title":"Clin Genet"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0220","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/j.1447-0756.1994.tb00439.x","article-title":"Primary clear cell adenocarcinoma of the fallopian tube with brain metastasis: a case report","volume":"20","author":"Ryuko","year":"1994","journal-title":"Asia Oceania J Obstet Gynaecol"},{"issue":"10","key":"10.1016\/j.jocn.2025.111602_b0225","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2019-231678","article-title":"Atypical radiological presentation of multiple cystic brain metastases from lung cancer simulating neurocysticercosis","volume":"12","author":"Barbone","year":"2019","journal-title":"BMJ Case Rep"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0230","article-title":"Cutaneous and cerebral metastases from primary peritoneal clear cell carcinoma","volume":"14","author":"Alves","year":"2022","journal-title":"Cureus J Med Sci"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0235","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11748-009-0481-6","article-title":"Thymic clear cell carcinoma","volume":"58","author":"Nakano","year":"2010","journal-title":"Gen Thorac Cardiovasc Surg"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0240","doi-asserted-by":"crossref","first-page":"85","DOI":"10.31768\/2312-8852.2018.40(1):85-87","article-title":"A long survival of a patient with brain metastasis of unknown site of the primary tumor","volume":"40","author":"Ben Kridis","year":"2018","journal-title":"Exp Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0245","doi-asserted-by":"crossref","DOI":"10.1186\/s13256-022-03321-x","article-title":"Differential abscopal effect in extracranial and intracranial lesions after radiotherapy alone for vertebral bone metastasis of unknown primary: a case report","volume":"16","author":"Ishikawa","year":"2022","journal-title":"J Med Case Reports"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0250","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ygyno.2007.01.014","article-title":"Diethylstilbestrol (DES)-induced clear cell adenocarcinoma of the vagina metastasizing to the brain","volume":"105","author":"Lin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0255","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/1097-0142(20000901)89:5<1095::AID-CNCR19>3.0.CO;2-H","article-title":"Brain metastases in patients with no known primary tumor: the role of stereotactic radiosurgery","volume":"89","author":"Maesawa","year":"2000","journal-title":"Cancer: Interdiscipl Int J Am Cancer Soc"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0260","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1006\/gyno.1999.5471","article-title":"Behavior of estrogen-associated female genital tract cancer and its relation to neoplasia following intrauterine exposure to diethylstilbestrol (DES)","volume":"76","author":"Herbst","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.21873\/cdp.10080","article-title":"Complete response of a mutated BRCA2 metastatic clear cell endometrial adenocarcinoma to the poly (ADP ribose) polymerase (PARP) inhibitor olaparib","volume":"2","author":"Anzellini","year":"2022","journal-title":"Cancer Diagn Progn"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0270","first-page":"52","article-title":"Paclitaxel-platinum combination chemotherapy for advanced or recurrent ovarian clear cell adenocarcinoma: a multicenter trial","volume":"16","author":"Utsunomiya","year":"2006","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0275","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1525-1438.2007.01158.x","article-title":"Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study","volume":"18","author":"Takano","year":"2008","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0280","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ygyno.2013.04.469","article-title":"Involved-field radiation therapy for locoregionally recurrent ovarian cancer","volume":"130","author":"Brown","year":"2013","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0285","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ygyno.2007.07.079","article-title":"Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary","volume":"107","author":"Nagai","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0290","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3171\/jns.2003.98.2.0342","article-title":"Radiosurgery in patients with renal cell carcinoma metastasis to the brain: long-term outcomes and prognostic factors influencing survival and local tumor control","volume":"98","author":"Sheehan","year":"2003","journal-title":"J Neurosurg"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0295","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(23)00513-2","article-title":"Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0300","doi-asserted-by":"crossref","first-page":"e273","DOI":"10.1016\/j.clgc.2018.11.006","article-title":"Stereotactic radiosurgery for multiple brain metastases from renal-cell carcinoma","volume":"17","author":"Wardak","year":"2019","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0305","doi-asserted-by":"crossref","first-page":"544","DOI":"10.2214\/AJR.14.14099","article-title":"Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors","volume":"206","author":"Sun","year":"2016","journal-title":"Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0310","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ctrv.2013.05.002","article-title":"Stereotactic radiosurgery in the treatment of brain metastases: the current evidence","volume":"40","author":"Lippitz","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jocn.2025.111602_b0315","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/636918","article-title":"Stereotactic radiosurgery for renal cancer brain metastasis: prognostic factors and the role of whole-brain radiation and surgical resection","volume":"2015","author":"Ippen","year":"2015","journal-title":"J Oncol"},{"issue":"8","key":"10.1016\/j.jocn.2025.111602_b0320","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1002\/cncr.20167","article-title":"Stereotactic radiosurgery for multiple brain metastases from breast carcinoma: feasibility and outcome of a local treatment concept","volume":"100","author":"Muacevic","year":"2004","journal-title":"Cancer: Interdiscipl Int J Am Cancer Soc"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0325","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3171\/2010.8.JNS10461","article-title":"Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer: clinical article","volume":"114","author":"Kondziolka","year":"2011","journal-title":"J Neurosurg JNS"},{"key":"10.1016\/j.jocn.2025.111602_b0330","article-title":"Analysis of long-term outcomes and prognostic factors in patients with non\u2014small cell lung cancer brain metastases treated by gamma knife radiosurgery","volume":"102(Special_Supplement):75\u201380","author":"Gerosa","year":"2005","journal-title":"J Neurosurg"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0335","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1093\/neuonc\/noy159","article-title":"Outcomes following stereotactic radiosurgery for small to medium-sized brain metastases are exceptionally dependent upon tumor size and prescribed dose","volume":"21","author":"Moraes","year":"2019","journal-title":"Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0340","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ijrobp.2020.10.034","article-title":"Tumor control probability of radiosurgery and fractionated stereotactic radiosurgery for brain metastases","volume":"110","author":"Redmond","year":"2021","journal-title":"Int J Radiat Oncol* Biol* Phys"},{"key":"10.1016\/j.jocn.2025.111602_b0345","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3389\/fonc.2020.00781","article-title":"Tumor primary site and histology subtypes role in radiotherapeutic management of brain metastases","volume":"10","author":"Khan","year":"2020","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0350","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s11060-009-0073-4","article-title":"The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline","volume":"96","author":"Linskey","year":"2010","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0355","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1038\/s41467-024-47998-8","article-title":"Response of treatment-naive brain metastases to stereotactic radiosurgery","volume":"15","author":"Ene","year":"2024","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jocn.2025.111602_b0360","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1002\/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5","article-title":"Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum\u2010based chemotherapy","volume":"88","author":"Sugiyama","year":"2000","journal-title":"Cancer: Interdiscipl Int J t Am Cancer Soc"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0365","article-title":"Clinical features, survival and prognostic factors of glycogen-rich clear cell carcinoma (GRCC) of the breast in the U.S","volume":"8","author":"Zhou","year":"2019","journal-title":"Population J Clin Med"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0370","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.ygyno.2007.04.032","article-title":"The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a gynecologic oncology group study","volume":"106","author":"McMeekin","year":"2007","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0375","doi-asserted-by":"crossref","first-page":"187","DOI":"10.21037\/tlcr.2018.10.13","article-title":"Clear cell adenocarcinoma of the lung: a SEER analysis","volume":"8","author":"Komiya","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"8","key":"10.1016\/j.jocn.2025.111602_b0380","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.3390\/cancers12082156","article-title":"Brain metastases from ovarian cancer: current evidence in diagnosis, treatment, and prognosis","volume":"12","author":"Borella","year":"2020","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0385","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.ygyno.2006.08.026","article-title":"Thromboembolic complications in patients with clear cell carcinoma of the ovary","volume":"104","author":"Matsuura","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.jocn.2025.111602_b0390","doi-asserted-by":"crossref","unstructured":"Yoshino K, Kurita T, Takahashi F, Nagase S, Board members of the 2021 Committee on Gynecologic Oncology of the Japan Society of Obstetrics and Gynecology. Annual report of the committee on gynecologic oncology, the Japan Society of Obstetrics and Gynecology: Annual patient report for 2019 and annual treatment report for 2014. J Obstetr Gynaecol Res. 2022;48(7):1570-1579. doi:10.1111\/jog.15284.","DOI":"10.1111\/jog.15284"},{"key":"10.1016\/j.jocn.2025.111602_b0395","unstructured":"Rendi MH, Garcia RL, Dizon DS. Epithelial carcinoma of the ovary, fallopian tube, and peritoneum: histopathology. Available via www uptodate com Published. Published online 2016."},{"key":"10.1016\/j.jocn.2025.111602_b0400","first-page":"A102","article-title":"250\u2005Differing risk of ovarian clear cell carcinoma in asian subpopulations","volume":"30","author":"Chow","year":"2020","journal-title":"Int J Gynecol Cancer"},{"issue":"18","key":"10.1016\/j.jocn.2025.111602_b0405","doi-asserted-by":"crossref","first-page":"6422","DOI":"10.1158\/1078-0432.CCR-05-0508","article-title":"Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer","volume":"11","author":"Zorn","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.jocn.2025.111602_b0410","first-page":"4722","article-title":"Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas","volume":"62","author":"Schwartz","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocn.2025.111602_b0415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jocn.2024.02.018","article-title":"Stereotactic radiosurgery for brain metastases arising from gynecological malignancies: a retrospective treatment outcome analysis","volume":"121","author":"Shopen","year":"2024","journal-title":"J Clin Neurosci"},{"issue":"4","key":"10.1016\/j.jocn.2025.111602_b0420","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1001\/jamaoncol.2024.6797","article-title":"Pembrolizumab in patients with advanced clear cell gynecological cancer: a phase 2 nonrandomized clinical trial","volume":"11","author":"Kristeleit","year":"2025","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jocn.2025.111602_b0425","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.590980","article-title":"Volumetric regression in brain metastases after stereotactic radiotherapy: time course, predictors, and significance","volume":"10","author":"Oft","year":"2021","journal-title":"Front Oncol"},{"issue":"24","key":"10.1016\/j.jocn.2025.111602_b0430","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1002\/cam4.4809","article-title":"Volumetric reduction of brain metastases after stereotactic radiotherapy: Prognostic factors and effect on local control","volume":"11","author":"Kanayama","year":"2022","journal-title":"Cancer Med"},{"key":"10.1016\/j.jocn.2025.111602_b0435","doi-asserted-by":"crossref","unstructured":"Farley JH, Brady WE, Fujiwara K, et al. A phase II evaluation of temsirolimus in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as first-line therapy in the treatment of stage III-IV clear cell carcinoma of the ovary. Published online 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.5531"},{"key":"10.1016\/j.jocn.2025.111602_b0440","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102991","article-title":"Durvalumab and tremelimumab in patients with advanced rare cancer: a multi-centre, non-blinded, open-label phase II basket trial","volume":"79","author":"Gupta","year":"2025","journal-title":"EClinicalMedicine"},{"issue":"8","key":"10.1016\/j.jocn.2025.111602_b0445","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/ijgc-2020-001604","article-title":"A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician\u2019s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)","volume":"30","author":"Ngoi","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.jocn.2025.111602_b0450","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. http:\/\/www nccn org\/professionals\/physician_gls\/PDF\/occult pdf. Published online 2008."},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0455","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41572-018-0055-y","article-title":"Brain metastases","volume":"5","author":"Achrol","year":"2019","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jocn.2025.111602_b0460","doi-asserted-by":"crossref","first-page":"v133","DOI":"10.1093\/annonc\/mdv305","article-title":"Cancers of unknown primary site: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Fizazi","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jocn.2025.111602_b0465","doi-asserted-by":"crossref","first-page":"402","DOI":"10.3389\/fonc.2019.00402","article-title":"Does cancer of unknown primary (CUP) truly exist as a distinct cancer entity?","volume":"9","author":"Bochtler","year":"2019","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0470","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.ijrobp.2009.07.012","article-title":"Radiosurgery for brain metastases from unknown primary cancers","volume":"77","author":"Niranjan","year":"2010","journal-title":"Int J Radiat Oncol* Biol* Phys"},{"issue":"2","key":"10.1016\/j.jocn.2025.111602_b0475","doi-asserted-by":"crossref","first-page":"107","DOI":"10.14791\/btrt.2016.4.2.107","article-title":"Optimal treatment decision for brain metastases of unknown primary origin: the role and timing of radiosurgery","volume":"4","author":"Han","year":"2016","journal-title":"Brain Tumor Res Treatm"},{"key":"10.1016\/j.jocn.2025.111602_b0480","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s11060-018-2745-4","article-title":"Identifying candidates for gamma knife radiosurgery among elderly patients with brain metastases","volume":"137","author":"Roh","year":"2018","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jocn.2025.111602_b0485","doi-asserted-by":"crossref","unstructured":"Haribhakti N, Elliott A, Walker P, et al. Genomic analysis of clear cell carcinoma. J Clin Oncol. 2022;40(16_suppl):5548\u20135548.","DOI":"10.1200\/JCO.2022.40.16_suppl.5548"},{"issue":"11","key":"10.1016\/j.jocn.2025.111602_b0490","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/modpathol.2017.67","article-title":"Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium","volume":"30","author":"Willis","year":"2017","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.jocn.2025.111602_b0495","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1186\/s12885-022-10478-7","article-title":"Immunohistochemical expression of PD-L1 and its correlation with microsatellite status in endometrial and ovarian clear cell carcinomas: a cross-sectional study","volume":"22","author":"Ghasemi","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.jocn.2025.111602_b0500","article-title":"Immunogenicity of clear cell ovarian cancer: Association with ARID1A loss, microsatellite instability and endometriosis","author":"Strickland","year":"2016","journal-title":"Published online"},{"issue":"11","key":"10.1016\/j.jocn.2025.111602_b0505","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1158\/2326-6066.CIR-22-0407","article-title":"The tumor microenvironment of clear-cell ovarian cancer","volume":"10","author":"Devlin","year":"2022","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.jocn.2025.111602_b0510","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1002\/ijc.34165","article-title":"The prevalence of mismatch repair deficiency in ovarian cancer: a systematic review and meta\u2010analysis","volume":"151","author":"Atwal","year":"2022","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.jocn.2025.111602_b0515","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1200\/JCO.19.02059","article-title":"Randomized phase II trial of nivolumab versus nivolumab and ipilimumab for recurrent or persistent ovarian cancer: an NRG oncology study","volume":"38","author":"Zamarin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0520","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jocn.2025.111602_b0525","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41379-020-00699-1","article-title":"Recurrent urothelial carcinoma-like FGFR3 genomic alterations in malignant Brenner tumors of the ovary","volume":"34","author":"Lin","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jocn.2025.111602_b0530","first-page":"25","article-title":"Targeted therapies: expanding the role of FGFR3 inhibition in urothelial carcinoma","author":"Zengin","year":"2022","journal-title":"In: Vol 40 Elsevier"},{"issue":"10","key":"10.1016\/j.jocn.2025.111602_b0535","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1002\/ijc.29279","article-title":"TERT promoter mutations in clear cell renal cell carcinoma","volume":"136","author":"Hosen","year":"2015","journal-title":"Int J Cancer"},{"issue":"36","key":"10.1016\/j.jocn.2025.111602_b0540","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/s41388-020-01405-w","article-title":"Targeting telomerase for cancer therapy","volume":"39","author":"Guterres","year":"2020","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.jocn.2025.111602_b0545","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1002\/path.5769","article-title":"A multi\u2010ethnic analysis of immune\u2010related gene expression signatures in patients with ovarian clear cell carcinoma","volume":"255","author":"Heong","year":"2021","journal-title":"J Pathol"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825005752?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586825005752?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T21:11:35Z","timestamp":1762290695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586825005752"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":109,"alternative-id":["S0967586825005752"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111602","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stereotactic radiosurgery for brain metastases from extra-renal clear cell carcinoma: A series of four patients and review of the literature","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2025.111602","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111602"}}